tailieunhanh - Studying clinical characteristics of brain magnetic resonance image in non small cell lung cancer patients with brain metastases

Objectives: To give a description of clinical characteristics of brain magnetic resonance image in patients with brain metastases from non-small cell lung cancer. Subjects and method: A prospective study on 104 patients with brain metastases from non-small cell lung cancer, from 2-2017 to 9-2018. | Journal of military pharmaco-medicine no1-2019 STUDYING CLINICAL CHARACTERISTICS OF BRAIN MAGNETIC RESONANCE IMAGE IN NON-SMALL CELL LUNG CANCER PATIENTS WITH BRAIN METASTASES Nguyen Minh Hai1; Nguyen Dinh Tien1; Pham Van Luan1 SUMMARY Objectives: To give a description of clinical characteristics of brain magnetic resonance image in patients with brain metastases from non-small cell lung cancer. Subjects and method: A prospective study on 104 patients with brain metastases from non-small cell lung cancer, from 2 - 2017 to 9 - 2018. Results: Mean age was 59, most of them under 65 years old (), male occupied , adenocarcinoma . EGFR (+) . Asymptomatic patients explained . Size of brain metastases ≤ 2 cm made up , 1 - 2 tumors constituted . Conclusion: Most patients with brain metastases from non-small cell lung cancer were males, under 65 years old with adenocarcinoma and asymptomatic histology. Size of brain metastases ≤ 2 cm and 1 - 2 tumors in brain were common. Brain metastases with ring enhancement was , peritumoral edema was . * Keywords: Non-small cell lung cancer; Brain metastases; Brain magnetic resonance image; Clinical characteristics. INTRODUCTION Lung cancer remains a leading cause of mortality with million deaths worldwide. An estimated 234,030 new cases occurred in the United States in 2018 with a median age at diagnosis of 70 and 64% of predominance for males. Approximately 84% of these lung cancers are non-small cell lung cancers (NSCLC). Despite improvements in systemic therapy, the survival rate for patients with stage IV disease is poor, with fewer than 5% of 5-year survival after diagnosis. The frequency of central nervous system involvement in NSCLC patients is reported to reach 40% and 25% to 30% of NSCLC patients have synchronous brain metastases (BMs) at the time of diagnosis [5, 8]. The recent, widespread use of magnetic resonance image (MRI) has led to the increased identification of .

• Y khoa - Dược
• Non small cell lung cancer
• Brain metastases
• Brain magnetic resonance image
• Clinical characteristics
• Whole brain radiation therapy
• Journal of Biology
• Epidermal growth factor receptor
• Nonsmall cell lung cancer
• Lung cancer
• Phosphoinositide kinase
• Quantitative reverse transcription polymerase chain reaction (qRT PCR)
• BMC Pulmonary Medicine
• Small cell lung cancer
• Traditional histopathology
• Certain limitations
• BMC Cancer
• Brain metastasis
• Tyrosine kinase inhibitors
• Tumor mutation burden
• Meta analysis
• SET domain containing 5
• ERK signaling
• Lymph node metastasis
• Oncogenic lncRNA
• Lung adenocarcinoma
• Therapeutic approaches
• Tumor protein 53
• Anaplastic lymphoma kinase
• Risk factors
• Post recurrence survival
• Overall recurrence
• Performance status
• Best supportive care
• Overall survival
• Immune checkpoint inhibitor
• Immune related adverse events
• Re challenge
• Fluorescence in situ hybridization
• Massive parallel sequencing
• Circulating biomarker
• Thrombospondin 1
• Tumor microenvironment
• Feasibility study
• Cytotoxic agents prolongs survival
• Cytotoxic agent plus bevacizumab
• Epidermal growth factor receptor mutation
• Tyrosine kinase inhibitor
• Stereotactic ablative radiation therapy
• Oligometastatic tumor
• Lung metastasis
• Colorectal carcinoma
• Dose response relationship
• EGFR mutation
• Targeted therapy
• Personalized medicine
• Radiologic biomarkers
• Angiogenesis inhibitors
• Tumor angiogenesis
• Uncommon mutations
• Real world
• Camphor cytotoxicity
• DNA damaging
• DNA protective
• Drug resistant human lung cancer cell lines
• Non small cell lung carcinoma
• EGFR mutated patients
• Personalized medicine for effective treatment
• Targeted therapeutic drugs is reviewed
• Mutation specific immunohistochemistry
• Modelling and simulation
• Computational oncology
• Malignant pleural mesothelioma
• Toxicity balance
• Low dose radiation
• T cells
• Intensity modulated radiation technique
• Genome Biology
• Splicing isoform
• Long read sequencing
• Aberrant splicing isoform
• Cancer cells